ß-1,6-glucan therapeutic antibody conjugates
US11865135B2 · kind B2 · utility
0Cited by
0References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 5, 2017 |
| Grant date | Jan 9, 2024 |
| Priority date | — |
| Expiry date | Jul 31, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/90
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention encompasses embodiments in which a therapeutic antibody is conjugated to β-1,6-glucan oligomers. Thus, the present invention includes, among other things, compositions including a therapeutic antibody conjugated to one or more β-1,6-glucan oligomers. The present invention further includes, among other things, methods of making and/or using such β-1,6-glucan conjugates. In certain embodiments, a β-1,6-glucan conjugate of the present invention is useful as a therapeutic or in a method of therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.